BOUNDLESS

Open new worlds of possibility for drug discovery and materials design

Explore our platform

Our physics-based computational platform leverages a deep understanding of physics, chemistry, and predictive modeling to accelerate innovation.

Our platform enables our collaborators to discover high-quality, novel molecules more rapidly, at lower cost, and we believe with a higher likelihood of success compared to traditional methods. We’re also harnessing this platform for our internal drug discovery programs.

We are proud to be leading this digital revolution.

Hear From Our Team

  • "We are driven to innovate. That’s why we invest heavily in R&D to ensure our continued scientific leadership."

    JOEL LEBOWITZ

    Executive Vice President & Chief Financial Officer

  • "We’re breaking new ground here – combining biological, structural and therapeutic insights at scale and using physics-based modeling tools to design compounds for unmet medical needs.”

    KAREN AKINSANYA

    Senior Vice President & Chief Biomedical Scientist

  • “Our innovative platform can be applied across industries, as the underlying physics is the same. We are working to accelerate the development of new materials in a wide array of industries.”

    DANIEL LEVINE

    Senior Scientist I, Materials Science

  • “We can draw a direct line from our platform to the discovery of new medicines. That’s exciting, and it drives us to keep improving our technology.”

    SATHESH BHAT

    Senior Director, Computational Chemistry

EXPLORE OUR PLATFORM

Our computational platform lets you explore chemical space and predict molecular behavior with a high degree of accuracy.

Learn more

OUR MISSION

Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered. Learn more about our commitment to innovation.

Learn more

OUR PIPELINE

We are advancing a portfolio of collaborative and wholly-owned drug discovery programs spanning a wide range of disease targets and indications. Explore our programs and meet our collaborators.

Learn more

Press Releases

Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery

January 8, 2020

Announcing Schrödinger Software Release 2019-4

November 21, 2019

Schrödinger Appoints Drug Discovery Veteran Nancy Thornberry to Board of Directors

September 24, 2019

Schrödinger Announces Expansion of Multi-Target Research Collaboration with Takeda and Achievement of First Significant Preclinical Milestone in Lead Program

September 5, 2019

Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery

September 4, 2019

Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers

September 3, 2019

Announcing Schrödinger Software Release 2019-3

August 28, 2019

Schrödinger Expands Drug Discovery Partnership with Morphic Therapeutic

August 13, 2019

Schrödinger Appoints Veteran Pharma Financial Leader Gary Sender to Board of Directors

August 5, 2019

Schrödinger Receives Milestone Payment from Ono as Collaborative Program Advances

July 12, 2019
See All Press Releases
Back To Top